225Ac-J591

Actinium-225-labeled J591 · Weill Medical College of Cornell University

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for 225Ac-J591, covering 2022-12-06 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer [Phase 1, Phase 2]

See pricing